AHA2012:新诊心衰患者2年后患癌风险增加

2012-11-16 晓静 编译 医学论坛网

  美国心脏学会(AHA)2012科学年会公布的一项病例对照研究表明,新诊断的心力衰竭患者比那些无心衰患者的新发癌症诊断风险明显升高。且心衰患者一旦发生癌症,死亡风险增加48%。研究强调了管理心衰患者时对其进行非心血管疾病尤其是癌症监测的重要性。   研究者查阅了961例新诊断的心衰患者的癌症病史,并将同等数量、同时代基于社区的同等年龄和性别的人群作为对照组。结果显示,心衰患者更瘦,更有可能患有

  美国心脏学会(AHA)2012科学年会公布的一项病例对照研究表明,新诊断的心力衰竭患者比那些无心衰患者的新发癌症诊断风险明显升高。且心衰患者一旦发生癌症,死亡风险增加48%。研究强调了管理心衰患者时对其进行非心血管疾病尤其是癌症监测的重要性。

  研究者查阅了961例新诊断的心衰患者的癌症病史,并将同等数量、同时代基于社区的同等年龄和性别的人群作为对照组。结果显示,心衰患者更瘦,更有可能患有高血压、糖尿病、肥胖、慢性阻塞性肺疾病(COPD)、周围血管疾病和吸烟史以及急性心肌梗死。心衰患者和对照组的癌症病史分别为22%和23%。

  研究者还利用同等时间分别随访了596例新诊断心衰但无癌症病史的患者和相匹配的596例同时代的非心衰患者。

  在平均7.7年里对9201人—年进行随访,确定了244新诊断的癌症病例。多元分析后,心衰患者的新发癌症危险比为1.68 。与对照组相比,心衰患者的新诊断癌症更集中于患者晚年时候。心衰和癌症在癌症类型方面无明显相关性。

  研究者指出,患者在诊断为心衰后就诊率增加并在短期内进行一系列诊断评估检查,可能增加了原本未诊断的恶性肿瘤检出率。但在那些对新诊断心衰患者的密切随访研究中,患者在平均2年后癌症检出率才增加。

评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2061352, encodeId=5c0a20613525a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Apr 07 22:07:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267155, encodeId=aefb126e155dd, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373242, encodeId=d82013e324228, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413411, encodeId=b62e141341127, content=<a href='/topic/show?id=3f225299942' target=_blank style='color:#2F92EE;'>#患癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52999, encryptionId=3f225299942, topicName=患癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b2c2959841, createdName=zzc2212, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601310, encodeId=ed571601310ea, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2061352, encodeId=5c0a20613525a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Apr 07 22:07:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267155, encodeId=aefb126e155dd, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373242, encodeId=d82013e324228, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413411, encodeId=b62e141341127, content=<a href='/topic/show?id=3f225299942' target=_blank style='color:#2F92EE;'>#患癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52999, encryptionId=3f225299942, topicName=患癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b2c2959841, createdName=zzc2212, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601310, encodeId=ed571601310ea, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=)]
    2012-11-18 zhaohui6731
  3. [GetPortalCommentsPageByObjectIdResponse(id=2061352, encodeId=5c0a20613525a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Apr 07 22:07:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267155, encodeId=aefb126e155dd, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373242, encodeId=d82013e324228, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413411, encodeId=b62e141341127, content=<a href='/topic/show?id=3f225299942' target=_blank style='color:#2F92EE;'>#患癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52999, encryptionId=3f225299942, topicName=患癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b2c2959841, createdName=zzc2212, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601310, encodeId=ed571601310ea, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2061352, encodeId=5c0a20613525a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Apr 07 22:07:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267155, encodeId=aefb126e155dd, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373242, encodeId=d82013e324228, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413411, encodeId=b62e141341127, content=<a href='/topic/show?id=3f225299942' target=_blank style='color:#2F92EE;'>#患癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52999, encryptionId=3f225299942, topicName=患癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b2c2959841, createdName=zzc2212, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601310, encodeId=ed571601310ea, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2061352, encodeId=5c0a20613525a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Apr 07 22:07:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267155, encodeId=aefb126e155dd, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373242, encodeId=d82013e324228, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413411, encodeId=b62e141341127, content=<a href='/topic/show?id=3f225299942' target=_blank style='color:#2F92EE;'>#患癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52999, encryptionId=3f225299942, topicName=患癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b2c2959841, createdName=zzc2212, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601310, encodeId=ed571601310ea, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Sun Nov 18 06:07:00 CST 2012, time=2012-11-18, status=1, ipAttribution=)]
    2012-11-18 lq0307

相关资讯

普拉克索与心衰危险关系尚无定论

  2012年9月19日,美国食品与药物管理局(FDA)发表药物安全信息称,治疗帕金森病和不宁腿综合征药普拉克索可能增加患者心力衰竭(以下简称心衰)危险。但最近的研究结果显示,该药的潜在心衰危险还需进一步研究。   普拉克索是多巴胺受体激动剂。FDA分别于2008年和2010年收到了有关普拉克索的报告。报告显示,服用普拉克索的患者(n=12/4157)比服用安慰剂(n=4/2820)患者的新诊断

JAMA:心衰病人服用高血压药物与死亡风险的增加没有关系

4月11日,国际杂志《美国医学会杂志》JAMA上的一项研究披露,尽管观察性的研究提示,氯沙坦这种主要用于治疗高血压的药物与同类药物(血管紧张素Ⅱ受体阻滞剂[ARBs])中的其它药物相比可能与心衰患者死亡风险的增加有关,但一则包括了近6,500名患者的分析发现,总的来说,与ARB坎地沙坦的使用相比,氯沙坦的使用与全因死亡或心血管性死亡的增加无关。 丹麦哥本哈根Statens Serum研究所的He

FDA:普拉克索是否增加心衰危险尚无定论

 2012年9月19日,美国食品与药物管理局(FDA)发表药物安全信息称,治疗帕金森病和不宁腿综合征药普拉克索可能增加患者心衰危险。但最近的研究结果显示,该药的潜在心衰危险还需进一步研究。   普拉克索是多巴胺受体激动剂。FDA分别于2008年和2010年收到了有关普拉克索的报告。报告显示,服用普拉克索的患者(n=12/4157)比服用安慰剂(n=4/2820)患者的新诊断心衰发

AHA2012年会:心肌干细胞输注促进梗死心肌再生

     在11月6日的美国心脏学会(AHA)2012科学年会上,美国一项有关干细胞输注治疗缺血性心肌病的试验(SCIPIO)引人注目,该试验研究了心肌干细胞(CSCs)而不是骨髓干细胞对心力衰竭患者的益处,而且初步结果令人振奋。   SCIPIO是一个随机开放标签的1期临床试验,研究对象为心肌梗死后左室射血分数(LVEF)<40%的心衰患者,使用c-KIT-阳性CSCs。细胞来源于患者

BMJ:绝经早期接受激素替代治疗(HRT)可显著降低心力衰竭风险

  丹麦一项研究显示,女性于绝经早期接受激素替代治疗(HRT)10年,可显著降低其死亡、心力衰竭或心肌梗死(MI)风险,且不会显著增加癌症、静脉栓塞或卒中风险。论文10月9日在线发表于《英国医学杂志》(BMJ)。   该研究于1990~1993年纳入1006名45~58岁的健康女性,均新近绝经,或有绝经症状且血清促卵泡激素处于绝经水平,并将其随机分至接受HRT组(T组,n=502)和对照组(C组

伊伐布雷定:减慢心率又添适应证

    2012年2月9日欧洲药品监管局(EMEA)正式批准单纯降低心率的新药伊伐布雷定用于合并收缩功能异常的慢性心力衰竭(心衰)治疗。该适应证的获批主要基于SHIFT研究结果,即伊伐布雷定在β受体阻滞剂等传统药物治疗的基础上可使心衰患者的主要终点(心血管死亡和心衰恶化住院)显著降低l8%.心衰死亡风险显著降低26%。此前,伊伐布雷定在2005和2009年分别在欧洲获